Request permission to file an abbreviated new animal drug application (ANADA) for a generic compressed soft chewable tablet for Trilostane that differs from the pioneer product, Vetoryl, sponsored by Dechra Ltd. under NADA 141-291 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2025-P-6404

Request permission to file an abbreviated new animal drug application (ANADA) for a generic compressed soft chewable tablet for Trilostane that differs from the pioneer product, Vetoryl, sponsored by Dechra Ltd. under NADA 141-291

Documents

Comments

Description

CLOSED

Key Dates

Comment Period OpensNov 24, 2025

Documents

Type	Title	Posted	Comments	Status
Other	Final Response Letter from FDA CVM to Felix Pharmaceuticals Pvt. Ltd.	Feb 26, 2026	--

Keywords

CVM

Suitability Petition

Felix Pharmaceuticals Pvt. Ltd.

an abbreviated new animal drug application

(ANADA) for a generic compressed soft

chewable tablet for Trilostane that differs from

the pioneer product, Vetoryl,

sponsored by Dechra, Ltd. under NADA 141-291

Data from Regulations.gov